LR-CHOP-21 regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R2CHOP regimen ;Revlimid-Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen
Overview
LR-CHOP-21 regimen refers to a chemotherapeutic regimen consisting of lenalidomide (revlimid), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolonegiven every 21 days has high activity in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Regimen
L/RLenalidomide (Revlimid)
RRituximab
CCyclophosphamide
HDoxorubicin (Hydroxydoxorubicin Hydrochloride)
OVincristine (Oncovin)
PPrednisolone
Indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
References
- ↑ 1.0 1.1 Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G; et al. (2014). “Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial”. Lancet Oncol. 15 (7): 730–7. doi:10.1016/S1470-2045(14)70191-3. PMID 24831981.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH